Drugs / Levocabastine
Levocabastine
also known as
LEVO · LEV · Levocabastina · Levocabastine HCL · LEVOCABASTINE HYDROCHLORIDE · Livostin · Livostin direct · Livostine · +2 more
Small molecule targets HRH1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LIVOSTIN | — | 1996-06-10 | fda.gov ↗ |
| Approved | US (FDA) | LIVOSTIN | — | 1993-11-10 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01962467 | Oct 2013 → Feb 2014 | allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT01949051 | Oct 2013 → Feb 2014 | allergic rhinitis | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT01957202 | Oct 2013 → Feb 2014 | allergic rhinitis | GlaxoSmithKline | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT04002349 | Jul → Dec 2019 | — | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02498509 Comparator | May 2015 → Mar 2016 | perennial allergic rhinitis | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levocabastine | “A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine With Levocabastine and Fluticasone Furoate Alone” NCT01962467 ↗ |
| Known as | LEV | “The purpose of the study is to determine the relative bioavailability of Fluticasone Furoate (FF) and Levocabastine (LEV), when each is administered alone and as FF/LEV Fixed...” NCT01962467 ↗ |
| Known as | LEVO | “OBJECTIVES: To test the hypothesis that intranasal levocabastine (LEVO) may provide benefits as a oncedaily treatment in allergic rhinitis (AR), this non-inferiority study...” PMID 26249767 ↗ Oct 20151“OBJECTIVE: To compare the effects of intranasal fluticasone furoate (FF)/levocabastine (LEVO) fixed-dose combination (FDC) with each component alone” PMID 25900517 ↗ Aug 2015 |
| Known as | Levocabastina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615438 ↗ |
| Known as | Levocabastine HCL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02498509 ↗ |
| Known as | LEVOCABASTINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615438 ↗ |
| Known as | Livostin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615438 ↗ |
| Known as | Livostin direct | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615438 ↗ |
| Known as | Livostine | “Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)” NCT04002349 ↗ |
| Known as | Livostinet | “Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray” NCT04002349 ↗ |
| Known as | R 50,547 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615438 ↗ |
| Action | Inhibit | “Histamine H1 receptor antagonist” CHEMBL1615438 ↗ |
| Modality | Small molecule | — CHEMBL1615438 ↗ |
| Route | Intranasal | “Intranasal aqueous 50 mcg microsuspension of levocabastine” NCT01949051 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1615438 ↗ |